(Q30521133)

English

Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

prostate cancer

1 reference

based on heuristic

inferred from title

Matthew R Sydes

object named as

Matthew R Sydes

2

0 references

object named as

Noel W Clarke

4

0 references

1 reference

ORCID Public Data File 2021

author name string

Nicholas D James

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Malcolm D Mason

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

John Anderson

5

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

David P Dearnaley

6

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

John Dwyer

7

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Gordana Jovic

8

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Alastair W S Ritchie

9

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

J Martin Russell

10

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Karen Sanders

11

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

George N Thalmann

12

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Gianfilippo Bertelli

13

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Alison J Birtle

14

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Joe M O'Sullivan

15

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Andrew Protheroe

16

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Denise Sheehan

17

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Narayanan Srihari

18

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Mahesh K B Parmar

19

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

STAMPEDE investigators

20

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

publication date

26 March 2012

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

13

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

5

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

549-558

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

An update on androgen deprivation therapy for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

Speeding up the evaluation of new agents in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

20 June 2018

The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

26 November 2018

Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

26 November 2018

Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3398767

26 November 2018

Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22452894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/22452894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclooxygenase-2 inhibitors in tumorigenesis (part I)

1 reference

https://pubmed.ncbi.nlm.nih.gov/22452894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclooxygenase-2 inhibitors in tumorigenesis (Part II)

1 reference

https://pubmed.ncbi.nlm.nih.gov/22452894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

COX-2 inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/22452894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/S1470-2045(12)70088-8

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30521133&oldid=1973150023"